abstract |
Compounds of formulae (IA) and (IB): wherein R1, R2, R3, Ar1 and X are as defined in the specification, are endothelin antagonists. The compounds are therefore useful in the treatment of a variety of conditions mediated by endothelin, such as restenosis, renal failure and systemic and pulmonary hypertension. |